Company intelligence

NAMS

NewAmsterdam Pharma Company N.V. · NASDAQ · Healthcare

Price$27.34+1.82% · +$0.49

Market cap3.2BEquity value

P / E-12.7Trailing ratio

Volume1.99MLatest session

Market data

NAMS price chart

TradingView

Related signals

1 min delayed

Browse public NAMS signals with their source context and measured market impact. Open any signal for its permanent analysis page.

NAMSDec 10, 2024+6.68% since signal

Why Is NewAmsterdam Pharma Stock Trading Higher On Tuesday?

NAMS achieved significant LDL-C reduction of 33% in Phase 3 trial. Clinical trial demonstrated a 21% reduction in major adverse cardiac events. Obicetrapib was well-tolerated with comparable safety results to placebo. Stock price rose 33.6% following the positive trial results. Analyst predicts obicetrapib has blockbuster sales potential.

View signal analysis

NAMSAug 28, 2024-3.25% since signal

NewAmsterdam Pharma's Cholesterol Drug To See Blockbuster Sales, Bullish Analyst Sees Massive Upside

Needham initiates coverage on NewAmsterdam Pharma with a Buy rating. Obicetrapib showed significant LDL-C reduction in Phase 3 trials. Potential blockbuster sales of over $2 billion anticipated for Obicetrapib. Upcoming trial results in Q4 2024 and Q1 2025 may validate efficacy. New patent extends Obicetrapib protection until July 2043.

View signal analysis

Research